Verywell Health on MSN2h
Eating Too Much Red Meat Increases the Risk of Fatty Liver Disease
Medically reviewed by Jonathan Purtell, RDN Red and processed meat—like bacon and hot dogs—is linked to a higher risk of ...
Verywell Health on MSN21h
Menopause Raises the Risk of Fatty Liver Disease. Changing Hormones May Be the Reason Why
Women experiencing menopause are more likely to develop MASH, a severe form of nonalcoholic fatty liver disease, than men of ...
BioSpace1d
7 Late-Stage MASH Candidates That Could Reshape the Market
Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...
Medscape13d
EMA Approves AI Tool for MASH Clinical Trials
The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...
The American Journal of Managed Care12d
GLP-1 RAs May Offer Broad Hepatic Benefits in MASH
Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...
Fierce Biotech13d
Ascletis slashes funding for former core programs in pivot to obesity
Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from ...
Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...